If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.

FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.

What if you'd invested in Halozyme Therapeutics (HALO) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?

Halozyme Therapeutics' Business In-Depth

With that in mind, let's take a look at Halozyme Therapeutics' main business drivers.

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting the tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.

The company’s ENHANZE drug delivery technology helps in developing the SC formulation of drugs. Several companies, including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others, are using this technology for developing the SC formulation of their currently marketed drugs. It also recognizes revenues from the sale of drug products to its collaboration partners for the development of drugs using its ENHANZE platform.

Halozyme now has several marketed partnered drugs based on this technology.

Halozyme currently earns royalties on sales of various commercial products by its partners. The ENHANZE platform was developed based on the company’s patented recombinant human hyaluronidase enzyme (rHuPH20).

The company’s commercial portfolio of products includes Hylenex Recombinant and Xyosted, with the latter acquired from Antares Pharma in 2022.

Halozyme derives the majority of its revenues from royalties on sales of partnered drugs. Royalties constituted more than 55% of the company’s total revenues in 2025. Halozyme generated total revenues of $1.39 billion in 2025, up 38% year over year.

Bottom Line

Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Halozyme Therapeutics, if you bought shares a decade ago, you're likely feeling really good about your investment today.

A $1000 investment made in September 2016 would be worth $10,866.33, or a gain of 986.63%, as of September 1, 2026, according to our calculations. This return excludes dividends but includes price appreciation.

In comparison, the S&P 500's gained 254.05% and the price of gold went up 225.98% over the same time frame.

Going forward, analysts are expecting more upside for HALO.

Halozyme's second-quarter earnings and revenues beat estimates. The company has collaboration deals related to its ENHANZE technology with several large pharma companies that generate royalties and milestone payments. This, in return, is driving the company's top line. Robust demand for argenx's Vyvgart Hytrulo and the subcutaneous formulation of J&J's Darzalex is boosting royalties and the top line. The momentum is likely to continue for the rest of 2026. Halozyme is also focused on signing new collaboration deals to aid growth. However, blockbuster drugs like Herceptin and Rituxan, which utilize ENHANZE technology, are now facing biosimilar competition, resulting in potential decreased revenues from royalties. High dependence on partners for revenues in the form of royalties remains a major concern.

The stock is up 29.44% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2026. The consensus estimate has moved up as well.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research